How many drugs treat Dysmenorrhea?

Drug Landscape tracks 10 marketed treatments for Dysmenorrhea (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/dysmenorrhea.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dysmenorrhea — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dysmenorrhea (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Dysmenorrhea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Slynd	DROSPIRENONE	Exeltis Usa Inc	Progestin	Mineralocorticoid receptor	2019-01-01
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	Progestin	Progesterone receptor	2010-01-01
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Voltaren	DICLOFENAC	Hisamitsu Pharmaceutical Co., Inc	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	1988-01-01
Arthrotec	Diclofenac Sodium	Pfizer	diclofenac	Acid-sensing ion channel 3	1988-01-01
Aleve	naproxen	Generic (originally Syntex)	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Pyrilamine	mepyramine	Impax Labs	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01
Lithobid	lithium carbonate	Generic (multiple manufacturers)	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Advil	ibuprofen	Generic (originally Boots Group)	Nonsteroidal Anti-inflammatory Drug [EPC]	Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2	1969-01-15
Jadelle	LEVONORGESTREL	Fdn Consumer	Progestin	Progesterone receptor	1968-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Dysmenorrhea
Exeltis Usa Inc · 1 drug in Dysmenorrhea
Fdn Consumer · 1 drug in Dysmenorrhea
Generic (multiple manufacturers) · 1 drug in Dysmenorrhea
Generic (originally Boots Group) · 1 drug in Dysmenorrhea
Generic (originally Syntex) · 1 drug in Dysmenorrhea
Hikma · 1 drug in Dysmenorrhea
Hisamitsu Pharmaceutical Co., Inc · 1 drug in Dysmenorrhea
Impax Labs · 1 drug in Dysmenorrhea
M.D. Anderson Cancer Center · 1 drug in Dysmenorrhea
Memorial Sloan Kettering Cancer Center · 1 drug in Dysmenorrhea
Merck & Co. · 1 drug in Dysmenorrhea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dysmenorrhea:

Cite this brief

Drug Landscape (2026). Dysmenorrhea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dysmenorrhea. Accessed 2026-06-10.

Dysmenorrhea full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing